Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $94.75 and last traded at $94.12, with a volume of 168048 shares trading hands. The stock had previously closed at $93.31. Wall Street Analysts Forecast Growth A number of […]
Tekla Capital Management LLC lowered its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 75.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,426 shares of the company’s stock after selling 199,650 shares during the period. Tekla Capital Management LLC […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares gapped down before the market opened on Tuesday . The stock had previously closed at $88.11, but opened at $82.50. Apellis Pharmaceuticals shares last traded at $84.71, with a volume of 597,729 shares. Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on APLS shares. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price boosted by Citigroup from $88.00 to $106.00 in a report published on Monday morning, The Fly reports. Several other research firms have also commented on APLS. HC Wainwright increased their price target on shares of Apellis Pharmaceuticals from $87.00 to $100.00 in a research report […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price objective upped by stock analysts at Bank of America from $112.00 to $114.00 in a research note issued to investors on Friday, The Fly reports. Bank of America‘s price target indicates a potential upside of 35.12% from the stock’s current price. Several other brokerages have also […]